Zobrazeno 1 - 10
of 351
pro vyhledávání: '"Charles A, Peloquin"'
Autor:
Xueyi Chen, Bhavatharini Arun, Oscar J. Nino-Meza, Mona O. Sarhan, Medha Singh, Byeonghoon Jeon, Kishor Mane, Maunank Shah, Elizabeth W. Tucker, Laurence S. Carroll, Joel S. Freundlich, Charles A. Peloquin, Vijay D. Ivaturi, Sanjay K. Jain
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first
Externí odkaz:
https://doaj.org/article/12b747e27b024b34afbe5771b810380b
Autor:
Marie Nancy Séraphin, Julia Bellot, Emily Klann, Maria Ukhanova, Florence G. Saulsberry, Charles A. Peloquin, Volker Mai
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Tuberculosis (TB) preventive therapy (TPT) is an effective strategy to eliminate TB in low-incidence settings. Shorter TPT regimens incorporating the antimicrobial class of rifamycins are designed to improve adherence and completion rates bu
Externí odkaz:
https://doaj.org/article/1e04c22e3e8145f8834ea37a5e4faa4d
Publikováno v:
BMC Research Notes, Vol 16, Iss 1, Pp 1-4 (2023)
Abstract Objective We present 16s rRNA gene sequencing (V1-V2 region) and sample data from a pilot observational cohort study to describe the gut microbiota dynamics of subjects with latent tuberculosis infection (LTBI) treated with daily 600 mg rifa
Externí odkaz:
https://doaj.org/article/29872272bffa4880b4eec674bc81671a
Autor:
Mohammad H. Alshaer, PharmD, PhD, Roy Williams, MPH, Mays J. Mousa, PharmD, MBA, Kaitlin M. Alexander, PharmD, Kelly L. Maguigan, PharmD, Kayihura Manigaba, PharmD, Nicole Maranchick, PharmD, Bethany R. Shoulders, PharmD, Timothy W. Felton, MBBS, PhD, Sumith K. Mathew, MD, Charles A. Peloquin, PharmD
Publikováno v:
Critical Care Explorations, Vol 5, Iss 11, p e0993 (2023)
IMPORTANCE:. Sepsis and septic shock are major healthcare problems that need early and appropriate management. OBJECTIVES:. To evaluate the association of daily cefepime pharmacokinetic/pharmacodynamic (PK/PD) parameters with change in Sequential Org
Externí odkaz:
https://doaj.org/article/5bf159a8cfa740ee8799b467d4b4c8cf
Autor:
Filipa Mota, Camilo A. Ruiz-Bedoya, Elizabeth W. Tucker, Daniel P. Holt, Patricia De Jesus, Martin A. Lodge, Clara Erice, Xueyi Chen, Melissa Bahr, Kelly Flavahan, John Kim, Mary Katherine Brosnan, Alvaro A. Ordonez, Charles A. Peloquin, Robert F. Dannals, Sanjay K. Jain
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Pretomanid has been approved for use in cases of multi-drug resistant pulmonary tuberculosis, yet the penetration of this antibiotic into other target tissues is not well established. Authors provide insight on pretomanid pharmacokinetics in the cent
Externí odkaz:
https://doaj.org/article/f0a782321c4e4e36aa37ab969660b2e2
Autor:
Nicole F. Maranchick, Jessica Webber, Mohammad H. Alshaer, Timothy W. Felton, Charles A. Peloquin
Publikováno v:
Antibiotics, Vol 12, Iss 12, p 1696 (2023)
Background: The objective was to identify associations between beta-lactam pharmacokinetic/pharmacodynamic (PK/PD) targets and Gram-negative bacteria resistance emergence in patients. Methods: Retrospective data were collected between 2016 to 2019 at
Externí odkaz:
https://doaj.org/article/f04399bc18b84c49959109bff8c455cb
Autor:
Niklas Köhler, Hande Karaköse, Hans-Peter Grobbel, Doris Hillemann, Sönke Andres, Christina König, Barbara Kalsdorf, Thomas Theo Brehm, Laura Böttcher, Inna Friesen, Harald Hoffmann, Dražen Strelec, Dagmar Schaub, Charles A. Peloquin, Stefan Schmiedel, Laurent A. Decosterd, Eva Choong, Sebastian G. Wicha, Rob E. Aarnoutse, Christoph Lange, Patricia M. Sánchez Carballo
Publikováno v:
Pharmaceutics, Vol 15, Iss 11, p 2543 (2023)
The treatment of drug-resistant Mycobacterium tuberculosis relies on complex antibiotic therapy. Inadequate antibiotic exposure can lead to treatment failure, acquired drug resistance, and an increased risk of adverse events. Therapeutic drug monitor
Externí odkaz:
https://doaj.org/article/61ae5ab8f27c42b5814e8e04b54b71a2
Autor:
Carolina B. Maciel, Fernanda J. P. Teixeira, Katie J. Dickinson, Jessica C. Spana, Lisa H. Merck, Alejandro A. Rabinstein, Robert Sergott, Guogen Shan, Guanhong Miao, Charles A. Peloquin, Katharina M. Busl, Lawrence J. Hirsch
Publikováno v:
Neurological Research and Practice, Vol 4, Iss 1, Pp 1-9 (2022)
Abstract Background Nearly one in three unconscious cardiac arrest survivors experience post-anoxic status epilepticus (PASE). Historically, PASE has been deemed untreatable resulting in its exclusion from status epilepticus clinical trials. However,
Externí odkaz:
https://doaj.org/article/7278cb4a13c74708827fae6bb045f1b5
Autor:
Nicole F. Maranchick, Mohammad H. Alshaer, Alison G. C. Smith, Teona Avaliani, Mariam Gujabidze, Tinatin Bakuradze, Shorena Sabanadze, Zaza Avaliani, Maia Kipiani, Charles A. Peloquin, Russell R. Kempker
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Tuberculosis meningitis (TBM) is the most lethal form of TB. It is difficult to treat in part due to poor or uncertain drug penetration into the central nervous system (CNS). To help fill this knowledge gap, we evaluated the cerebrospinal
Externí odkaz:
https://doaj.org/article/42c5acdd55164357a1147124e1c4e097
Autor:
Riti Sharan, Shashank R. Ganatra, Dhiraj K. Singh, Journey Cole, Taylor W. Foreman, Rajesh Thippeshappa, Charles A. Peloquin, Vinay Shivanna, Olga Gonzalez, Cheryl L. Day, Neel R. Gandhi, Edward J. Dick Jr., Shannan Hall-Ursone, Smriti Mehra, Larry S. Schlesinger, Jyothi Rengarajan, Deepak Kaushal
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 18 (2022)
A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI). The aim of this study is to assess 3HP-mediated clearance of M. tuberculosis bacteria in macaques
Externí odkaz:
https://doaj.org/article/659732e8266a421b8e6775d23db444b0